Investors

Press Releases

Overview
Press Releases     
 Events + Presentations
Company Information
Stock Information
Analyst Coverage
SEC Filings
Corporate Governance
News Alerts

Recent Press Releases

Vallon Pharmaceuticals Provides Update on Recent Pipeline and Corporate Advancements
October 12, 2021

Vallon Pharmaceuticals Announces Formation of Scientific Advisory Board
September 14, 2021

Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit
August 11, 2021

Vallon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 10, 2021

Vallon Pharmaceuticals Announces Issuance of New European Patent Covering Method of Use and Composition of Matter for ADAIR
July 13, 2021

Vallon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 13, 2021

Vallon Pharmaceuticals Appoints Leanne Kelly as Chief Financial Officer
May 11, 2021

Vallon Pharmaceuticals to Present at the Q2 Virtual Investor Summit
May 07, 2021

Vallon Pharmaceuticals to Participate at the 4th Annual Neuroscience Innovation Forum
April 26, 2021

Vallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential Approval
April 13, 2021

Vallon Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Update
March 29, 2021

Vallon Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference
March 03, 2021

Vallon Pharmaceuticals Appoints Marella Thorell to Board of Directors
February 23, 2021

Vallon Pharmaceuticals Announces Closing of Initial Public Offering
February 12, 2021

Vallon Pharmaceuticals Announces Pricing of Initial Public Offering
February 09, 2021

Vallon Pharmaceuticals Announces Presentation of ADAIR Pharmacokinetics and Pharmacodynamic Data at the Virtual 2021 APSARD Annual Meeting
January 19, 2021

Data from Vallon Pharmaceuticals’ ADAIR Selected for Symposia Presentation at the Virtual 2021 APSARD Annual Meeting
January 08, 2021

Vallon Pharmaceuticals Presents Positive Data from Proof-of-Concept Intranasal Human Abuse Study of Its Investigational ADHD Stimulant, ADAIR
November 09, 2020

Vallon Newsroom